Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Luliconazole
Drug ID BADD_D01329
Description Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
Indications and Usage Luliconazole is indicated in adults aged 18 years and older for the topical treatment of fungal infections caused by Trichophyton rubrum and Epidermophyton floccosum, specifically tinea pedis, cruris, and corporis.
Marketing Status approved
ATC Code D01AC18
DrugBank ID DB08933
KEGG ID D01980
MeSH ID C112528
PubChem ID 3003141
TTD Drug ID D0U4XJ
NDC Product Code 70600-009; 99207-850; 68682-850; 66039-918
UNII RE91AN4S8G
Synonyms luliconazole | (2E)-((4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene)(1H-imidazol-1-yl)acetonitrile | 4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene-1-imidazolylacetonitrile | Lulicon | NND 502 | NND502 | NND-502
Chemical Information
Molecular Formula C14H9Cl2N3S2
CAS Registry Number 187164-19-8
SMILES C1C(SC(=C(C#N)N2C=CN=C2)S1)C3=C(C=C(C=C3)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Application site reaction12.07.01.006; 08.02.01.006--Not Available
Cellulitis23.11.02.004; 11.02.01.001--Not Available
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.003--Not Available
Tinea cruris23.11.03.010; 11.03.08.001--Not Available
Tinea pedis23.11.03.012; 11.03.08.004--Not Available
The 1th Page    1    Total 1 Pages